Stevens Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Stevens Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-11,142	Closed	-$154K	–	999
2016 Q4	$154K	Buy	+11,142	New	+$179K	0.01%	798
2016 Q2	–	Sell	-16,150	Closed	-$193K	–	1027
2016 Q1	$193K	Buy	16,150 +3,715	+30%	+$38.9K	0.01%	772
2015 Q4	$166K	Buy	+12,435	New	+$153K	0.01%	823
2015 Q3	–	Sell	-34,048	Closed	-$274K	–	1118
2015 Q2	$274K	Buy	+34,048	New	+$250K	0.01%	777

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Stevens Capital Management's LXRX Position: Q1 2017 in Review

Stevens Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2017, closing a stake of 11,142 shares — an estimated $154K sold.

Stevens Capital Management first reported a position in LXRX in Q2 2015 and held it in 4 quarters. The position peaked at $274K in Q2 2015. 137 funds tracked by Wall St. Rank hold LXRX as of Q1 2017.

Stevens Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Stevens Capital Management sold 11,142 Lexicon Pharmaceuticals shares in Q1 2017, an estimated $154K.
Stevens Capital Management first reported a position in Lexicon Pharmaceuticals in Q2 2015 and held it in 4 quarters.
Stevens Capital Management's Lexicon Pharmaceuticals position peaked at $274K in Q2 2015.
137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2017.

Based on Stevens Capital Management's 13F filing for Q1 2017, filed 8 May 2017.